Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
Medtronic
McKesson
Harvard Business School

Last Updated: June 28, 2022

KEVEYIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Keveyis patents expire, and what generic alternatives are available?

Keveyis is a drug marketed by Xeris and is included in one NDA.

The generic ingredient in KEVEYIS is dichlorphenamide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dichlorphenamide profile page.

Drug patent expirations by year for KEVEYIS
Drug Prices for KEVEYIS

See drug prices for KEVEYIS

DrugPatentWatch® Estimated Generic Entry Opportunity Date for KEVEYIS
Generic Entry Date for KEVEYIS*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for KEVEYIS

US Patents and Regulatory Information for KEVEYIS

KEVEYIS is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of KEVEYIS is See Plans and Pricing.

This potential generic entry date is based on TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting KEVEYIS

TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xeris KEVEYIS dichlorphenamide TABLET;ORAL 011366-002 Aug 7, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Moodys
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.